Hemgenix - A Gene Therapy for Hemophilia B
The Medical Letter on Drugs and Therapeutics · 2023
DOI: 10.58347/tml.2023.1668a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 7-mal zitiert (Crossref).
Abstract (Originalsprache)
Etranacogene dezaparvovec-drlb (Hemgenix – CSL Behring), an adeno-associated virus vector-based gene therapy, has been approved by the FDA for treatment of hemophilia B in adults who currently receive factor IX prophylaxis therapy or have had life-threatening or repeated, serious, spontaneous bleeding episodes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Zitieren
APA
(2023). Hemgenix - A Gene Therapy for Hemophilia B. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1668a
Vancouver
Hemgenix - A Gene Therapy for Hemophilia B. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1668a
BibTeX
@article{euvimed2023,
title = {Hemgenix - A Gene Therapy for Hemophilia B},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2023},
doi = {10.58347/tml.2023.1668a}
}
EUVIMED